The UK-based pharmaceutical company AstraZeneca is considering a merger with the US competitor Bristol Myers Squibb, according to a report by the Financial Times on Sunday. The discussions between the two companies have reportedly taken place over the last few months.
A merger between AstraZeneca and Bristol Myers Squibb would value the combined company at approximately $400 billion. If completed, the proposed deal would be among the largest in the history of the industry.
$400 billion
Estimated value of the joint company if the merger occurs
AstraZeneca and Bristol Myers Squibb did not immediately respond to a request for comment from CNBC.
Updates
AstraZeneca Plc has specifically explored the possibility of acquiring Bristol Myers Squibb Co.
AstraZeneca Plc has reportedly explored the possibility of acquiring Bristol Myers Squibb Co.
AstraZeneca has upgraded its listing on the New York Stock Exchange to enable direct share purchases by American investors while maintaining its presence on the London Stock Exchange. Additionally, the company has signed a $50bn deal with the Donald Trump administration to invest in US manufacturing and transatlantic research facilities. To avoid potential tariffs, AstraZeneca has also agreed to sell certain medicines at a discount to the US Medicaid programme.
AstraZeneca has explored an acquisition of Bristol Myers Squibb and is simultaneously pushing for a pivot towards America, which includes upgrading its NYSE listing to allow direct share purchases by American investors. Furthermore, the company has struck a $50bn deal with the Trump administration to invest in US manufacturing and transatlantic research facilities. Despite these moves, AstraZeneca insists it intends to remain headquartered in Cambridge, UK, and retain its listing on the London Stock Exchange.
AstraZeneca has explored an acquisition of Bristol Myers Squibb and upgraded its listing on the New York Stock Exchange to allow American investors to buy shares directly. Amid these discussions, the company has struck a $50bn deal with the Donald Trump administration to invest in US manufacturing and transatlantic research facilities. While the CEO described AstraZeneca as a 'very American company,' he has insisted that the firm intends to remain headquartered in Cambridge, UK.
AstraZeneca has upgraded its listing on the New York Stock Exchange to allow American investors to buy its shares directly while maintaining its London listing. Despite these moves and CEO Sir Pascal Soriot describing the firm as a 'very American company,' AstraZeneca has insisted it intends to keep its headquarters in Cambridge, UK. Additionally, the company has struck a $50bn deal with the Trump administration to invest in US manufacturing and transatlantic research facilities.
AstraZeneca has declined to comment on the merger discussions, while reports indicate the company's market value is approximately $264 billion. The potential deal, which would create one of the world's largest drugmakers, is valued at $400 billion, equivalent to £300 billion.
AstraZeneca has declined to comment on the merger discussions. The proposed deal, valued at $400 billion (£300 billion), would involve AstraZeneca, which has a market value of approximately $264 billion, and Bristol Myers Squibb.
An AstraZeneca representative declined to comment on the potential merger talks. While the deal's valuation remains estimated at $400 billion, AstraZeneca's current market value is approximately $264 billion, and Bristol Myers Squibb's market value stands at roughly $133 billion.
AstraZeneca has declined to comment on the potential merger discussions, and there is currently no binding agreement, formal offer, or established transaction timeline in place. If realized, the deal is projected to create the world's fourth-largest drugmaker by market value.
Despite the merger discussions, there is currently no binding agreement, formal offer, or transaction timeline in place. A representative for AstraZeneca has declined to comment on the potential deal, which is estimated to create the world's fourth-largest drugmaker by market value.
While a potential merger between AstraZeneca and Bristol Myers Squibb is being discussed, there is currently no binding agreement, formal offer, or transaction timeline in place. An AstraZeneca representative has declined to comment on the reported talks, and it remains unclear if the deal will come together.
AstraZeneca's shares dropped as much as 7% following reports of the potential merger, with London-listed shares trading 6.2% lower in early morning trading. While the deal remains speculative, there is currently no binding agreement, offer, or transaction timeline in place. Additionally, an AstraZeneca representative has declined to comment on the ongoing merger talks.
While there is currently no binding agreement, offer, or timeline for the potential merger, AstraZeneca shares dropped as much as 7% following the reports. A representative for AstraZeneca declined to comment on the merger talks, and analysts at Jefferies expressed perplexity regarding the news, noting that the company does not need financial engineering given its growth profile.
AstraZeneca has confirmed that it is conducting talks regarding a potential acquisition of Bristol Myers Squibb. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose in US pre-market trading. There is currently no binding agreement, formal offer, or established transaction timeline for the potential merger.
AstraZeneca has confirmed that it is conducting talks with Bristol Myers Squibb, though no binding agreement or transaction timeline has been established. Following the reports, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose in pre-market trading in the US.
AstraZeneca has confirmed that it is conducting talks with Bristol Myers Squibb, although no binding agreement, offer, or transaction timeline currently exists. Following the reports, AstraZeneca shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares saw an increase in US pre-market trading. The potential merger, which would create the world's fourth-largest drugmaker by market value, is expected to face extensive regulatory reviews in both the US and the UK.
AstraZeneca has confirmed that it is conducting talks with Bristol Myers Squibb. Following the reports, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose in pre-market trading in the US. Currently, there is no binding agreement, formal offer, or established transaction timeline for the potential merger.
AstraZeneca has confirmed it is conducting talks with Bristol Myers Squibb, though no binding agreement or timeline has been established. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose in US pre-market trading. Analysts have noted that a completed merger would likely create the world's fourth-largest drugmaker by market value.
AstraZeneca has confirmed it is conducting talks regarding a potential acquisition of Bristol Myers Squibb, though no binding agreement or transaction timeline currently exists. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. Analysts from Jefferies expressed skepticism, describing a potential deal as 'more than a head scratcher' given AstraZeneca's current growth profile.
AstraZeneca has confirmed that it is conducting merger talks with Bristol Myers Squibb, although no binding agreement or transaction timeline currently exists. Following the news, AstraZeneca shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. The potential deal, which could create the world's fourth-largest drugmaker by market value, is expected to face extensive regulatory scrutiny in both the U.S. and the UK.
AstraZeneca has confirmed that it is conducting talks with Bristol Myers Squibb regarding a potential merger. Following the news, AstraZeneca shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. Currently, there is no binding agreement, formal offer, or established transaction timeline in place.
AstraZeneca has confirmed that it is conducting talks with Bristol Myers Squibb, although no binding agreement or transaction timeline currently exists. Following the reports, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. Analysts have expressed skepticism regarding the strategic necessity of the deal, with one Jefferies analyst describing the potential merger as more than a head scratcher.
AstraZeneca has officially confirmed it is conducting merger discussions with Bristol Myers Squibb, though the company emphasized that no binding agreement, offer, or timeline currently exists. Following the report, AstraZeneca's shares dropped as much as 7% on the London Stock Exchange, while Bristol Myers Squibb's stock rose approximately 5% in U.S. premarket trading. Analysts from Jefferies described the potential deal as "more than a head scratcher," noting that AstraZeneca appears to have little strategic need for such a transformative acquisition.
AstraZeneca has confirmed that it is conducting talks between the two companies, although no binding agreement, offer, or transaction timeline has been established. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading.
AstraZeneca confirmed on Monday that it is conducting talks between the two companies, despite there being currently no binding agreement, offer, or transaction timeline. Following the reports, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. premarket trading.
AstraZeneca has confirmed it is conducting talks with Bristol Myers Squibb, though no binding agreement or timeline has been established. Following the reports, AstraZeneca's shares fell by as much as 7% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading.
AstraZeneca has confirmed that it is conducting talks with Bristol Myers Squibb, despite there being no binding agreement or transaction timeline in place. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. Analysts from Jefferies have expressed skepticism regarding the strategic necessity of the potential deal, describing it as more than a 'head scratcher.'
AstraZeneca has confirmed that it is conducting talks with Bristol Myers Squibb, though no binding agreement or transaction timeline currently exists. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb's shares rose approximately 5% in U.S. pre-market trading. Analysts from Jefferies expressed skepticism, noting that the potential deal would be 'more than a head scratcher' given AstraZeneca's existing growth profile.
AstraZeneca has confirmed that it is conducting merger talks with Bristol Myers Squibb, despite having no binding agreement or transaction timeline in place. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. The potential deal, which could create the world's fourth-largest drugmaker by market value, is expected to face extensive regulatory scrutiny in both the US and the UK.
AstraZeneca has confirmed that it is conducting talks with Bristol Myers Squibb, though no binding agreement or timeline currently exists. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. The potential merger, which could create the world's fourth-largest drugmaker by market value, is expected to face extensive regulatory scrutiny in both the US and the UK.
AstraZeneca has confirmed that it is conducting merger talks with Bristol Myers Squibb, though no binding agreement or transaction timeline has been established. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. A potential deal would create the world's fourth-largest drugmaker by market value but faces likely extensive regulatory scrutiny in both the US and the UK.
AstraZeneca has confirmed it is conducting talks with Bristol Myers Squibb, though no binding agreement or transaction timeline exists. Following the news, AstraZeneca's shares fell by as much as 7% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. Analysts have expressed skepticism regarding the strategic necessity of the deal, with Jefferies describing the potential merger as 'more than a head scratcher.'
AstraZeneca has confirmed it is conducting talks with Bristol Myers Squibb, though no binding agreement or timeline has been established. Following the report, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading.
AstraZeneca has confirmed that it is conducting talks with Bristol Myers Squibb, though there is currently no binding agreement or formal transaction timeline. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. The potential megamerger, which could create the world's fourth-largest drugmaker by market value, is expected to face extensive regulatory scrutiny in both the UK and the US.
AstraZeneca has confirmed that it is conducting talks with Bristol Myers Squibb, though no binding agreement or transaction timeline currently exists. Following the reports, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. premarket trading. Analysts from Jefferies described the potential deal as 'more than a head scratcher,' noting that the company has little obvious need for such a transformative acquisition.
AstraZeneca has confirmed it is conducting talks with Bristol Myers Squibb, though no binding agreement or transaction timeline currently exists. Following the announcement, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading.
AstraZeneca has confirmed that it is currently conducting talks with Bristol Myers Squibb, though no binding agreement or transaction timeline has been established. Following the news, AstraZeneca's shares fell by more than 6% on the London Stock Exchange, while Bristol Myers Squibb shares rose approximately 5% in U.S. pre-market trading. Analysts from Jefferies have expressed skepticism, describing a potential deal as 'more than a head scratcher' given AstraZeneca's current growth profile.
Contrary to initial reports, Reuters has confirmed on Wednesday that there are currently no ongoing merger discussions between AstraZeneca and Bristol Myers Squibb. High-ranking sources familiar with the matter also stated that no deal was ever up for debate and no discussions are taking place between the two companies.
AstraZeneca has confirmed that it is conducting talks between the two companies, though a representative for the firm declined to comment on the specific details of the merger. Despite these confirmations, a high-ranking source told Reuters that no agreement or discussions actually exist between the companies. Furthermore, Reuters reported on Wednesday that there are no ongoing merger discussions between AstraZeneca and Bristol Myers Squibb.
Contrary to earlier reports, Reuters has confirmed on Wednesday that there are no ongoing merger discussions between AstraZeneca and Bristol Myers Squibb. This follows conflicting reports from high-ranking sources stating that no deal was ever under debate and no discussions between the companies exist.
Reuters reported on Wednesday that there are no ongoing merger discussions between AstraZeneca and Bristol Myers Squibb, contradicting earlier reports that the companies were exploring a potential deal — a reversal that came after AstraZeneca’s shares had plunged nearly 9% on merger speculation, while Bristol Myers Squibb’s shares rose over 4% in premarket trading.
Reuters reported on Wednesday that there are no ongoing merger discussions between AstraZeneca and Bristol Myers Squibb, contradicting earlier reports that the companies were in talks — a reversal that followed conflicting statements, including from a high-ranking source who insisted no deal was ever under consideration and no discussions were taking place, despite AstraZeneca’s shares having plunged nearly 9% on the London Stock Exchange amid the speculation.
